The global obesity drug market is in the midst of its most competitive period in a generation. Since the approval of semaglutide as Wegovy and tirzepatide as Zepbound, pharmaceutical companies and investors have been watching closely for the next therapy capable of...
The obesity treatment landscape shifted decisively on 1 April 2026, when the US Food and Drug Administration approved Foundayo (orforglipron), an oral once-daily glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly. The decision marks the arrival of...
For most of the twentieth century, the global pharmaceutical industry operated on a straightforward geographic logic. Drugs were discovered and developed in North America and Western Europe, approved by the FDA and EMA, and then exported to the rest of the world. The...
AI developments are happening at breakneck speed, with every sector and industry seeking new opportunities to seize and capitalise upon. AI-driven research is creating a fundamental shift for pharmaceutical competitive intelligence, moving away from a reactive, manual...
The pharmaceutical press is having a very loud year. Eli Lilly's investigational triple-agonist retatrutide has produced the kind of phase 2 data that clinicians usually only see in editorials about the future, up to 24.2% mean body-weight reduction at 48 weeks in the...
AstraZeneca China Obesity Drug Deal: A $18.5 Billion Bet on the Future of Weight Management AstraZeneca announced on 30 January 2026, what has quickly become known as the AstraZeneca CSPC obesity deal, a landmark licensing and collaboration agreement with China's CSPC...
The life sciences sector is undergoing a significant transformation as it embraces sustainable and green manufacturing practices. These initiatives aim to reduce environmental impact, enhance operational efficiency, and meet the growing demand for eco-friendly...
Genentech has carried out another round of workforce reductions, cutting 87 positions at its South San Francisco headquarters. The layoffs, filed last week and set to take effect on September 15, were disclosed in a California Worker Adjustment and Retraining...
Life with haemophilia can be challenging but advances in science are helping people with haemophilia to lead active and fulfilling lives. What is Haemophilia? Haemophilia is a family of rare genetic blood disorders caused by a clotting factor deficiency, which...
US pharmaceutical heavyweight Merck has decided to halt its planned £1 billion expansion in the UK, criticising the government for a lack of substantial investment in the life sciences sector. The company, which operates under the name MSD in Europe, announced it will...
The Food and Drug Administration commissioner, Marty Makary, has selected George Tidmarsh, a former biotech executive and Stanford-affiliated pediatrician, to lead the agency’s drug regulatory arm, according to a source familiar with the matter. The appointment of...